Immunocytochemistry and the diagnosis of cutaneous lymphoma

Histopathology

Volumn 56, Issue 1, 2010, Pages 71-90

  Robson, Alistair ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cutaneous lymphoma; Diagnosis; Immunocytochemistry; Review

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BIOLOGICAL MARKER; CD2 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; EPITHELIAL MEMBRANE ANTIGEN; GRANZYME B; HERMES ANTIGEN; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; LEUKOSIALIN; PERFORIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL 6; T CELL INTRACELLULAR ANTIGEN 1; T LYMPHOCYTE ANTIGEN; T6 ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; B CELL LYMPHOMA; CANCER CLASSIFICATION; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CUTANEOUS GAMMA DELTA LYMPHOMA; DIFFERENTIAL DIAGNOSIS; ERYTHRODERMA; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCYTOCHEMISTRY; IMMUNODEFICIENCY ASSOCIATED LYMPHOMA; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; LYMPHOMATOID PAPULOSIS; MIXED CELL LYMPHOMA; MYCOSIS FUNGOIDES; NK T CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN BIOPSY; SKIN LYMPHOMA; SMALL MEDIUM CELL PLEOMORPHIC CD4+ T CELL LYMPHOMA; SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA; T CELL LEUKEMIA; T CELL LYMPHOMA;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; NEOPLASM PROTEINS; SKIN NEOPLASMS;

EID: 73449091184     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03457.x     Document Type: Review

References (144)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105 3768 3785.
2. Hodak E, David M, Maron L et al. CD4/CD8 double-negative epidermotropic cutaneous T-cell lymphoma: an immunohistochemical variant of mycosis fungoides. J. Am. Acad. Dermatol. 2006 55 276 284.
3. Ortonne N, Buyukbabani N, Delfau-Larue MH et al. Value of the CD8-CD3 ratio for the diagnosis of mycosis fungoides. Mod. Pathol. 2003 16 857 862.
4. Bergman R, Faclieru D, Sahar D et al. Immunophenotyping and T-cell receptor gamma gene rearrangement analysis as an adjunct to the histopathologic diagnosis of mycosis fungoides. J. Am. Acad. Dermatol. 1998 39 554 559.
5. Nuckols JD, Shea CR, Horenstein MG et al. Quantitation of intraepidermal T-cell subsets in formalin-fixed, paraffin-embedded tissue helps in the diagnosis of mycosis fungoides. J. Cutan. Pathol. 1999 26 169 175.
6. Harvell JD, Nowfar-Rad M, Sundram U. An immunohistochemical study of CD4, CD8, TIA-1 and CD56 subsets in inflammatory skin disease. J. Cutan. Pathol. 2003 30 108 113.
7. Wood GS, Edinger A, Hoppe RT et al. Mycosis fungoides skin lesions contain CD8+ tumour-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T-lymphocyte phenotype. J. Cutan. Pathol. 1994 21 151 156.
8. Cuitart J, Variakojis D, Kuzel T et al. Cutaneous CD8 T-cell infiltrates in advanced HIV infection. J. Am. Acad. Dermatol. 1999 41 722 727.
9. Ormsby A, Bergfield WF, Tubbs RR et al. Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: implications for diagnosis of mycosis fungoides in community practice. J. Am. Acad. Dermatol. 2001 45 405 413.
10. Cerroni L, Kerl H. Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Semin. Cutan. Med. Surg. 1999 18 64 70.
11. Vermeer MH, Geelen FAMJ, Kummer J et al. Expression of cytotoxic proteins by neoplastic T-cells in mycosis fungoides increases with progression from plaque to tumour stage disease. Am. J. Pathol. 1999 154 1203 1210.
12. Gambichler T, Bischoff S, Bechara FG et al. Expression of proliferation markers and cell cycle regulators in T-cell lymphoproliferative skin disorders. J. Dermatol. Sci. 2008 49 125 132.
13. van der Putte SCJ, Toonstra J, van Wichen DF et al. Aberrant immunophenotypes in mycosis fungoides. Arch. Dermatol. 1988 124 373 380.
14. Ralfkiaer E, Wollf-Sneedorff A, Thomsen K et al. Immunophenotypic studies in cutaneous T-cell lymphoma: clinical implications. Br. J. Dermatol. 1993 129 655 659.
15. Quick CM, Smoller BR, Hiatt KM. Fli-1 expression in mycosis fungoides. J. Cutan. Pathol. 2006 33 642 645.
16. Dummer R, Kamarashev J, Kempf W et al. Junctional CD8+ cutaneous lymphomas with non-aggressive clinical behaviour: a CD8+ variant of mycosis fungoides? Arch. Dermatol. 2002 138 199 203.
17. Kamarashev J, Burg G, Kempf W et al. Comparative analysis of histological and immunohistological features in mycosis fungoides and Sezary syndrome. J. Cutan. Pathol. 1998 25 407 412.
18. Ardigo M, Borroni G, Muscardin L et al. Hypopigmented mycosis fungoides in Caucasian patients: a clinicopathologic study of 7 cases. J. Am. Acad. Dermatol. 2003 49 264 270.
19. Shabrawi-Caelen LE, Cerroni L, Medeiros LJ et al. Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell lymphoma. Am. J. Surg. Pathol. 2002 26 450 457.
20. Wain EM, Orchard GE, Whittaker SJ et al. Outcome in 34 patients with juvenile-onset mycosis fungoides. Cancer 2003 98 2282 2290.
21. Groh V, Fabbi M, Hochstenbach F et al. Double-negative (CD4- CD8-) lymphocytes bearing T-cell receptor α and β chains in normal human skin. Proc. Natl Acad. Sci. USA 1989 86 5059 5063.
22. Fierro MT, Novelli M, Savoia P et al. CD45RA+ immunophenotype in mycosis fungoides: clinical, histopathological and immunophenotypical features in 22 patients. J. Cutan. Pathol. 2001 28 356 362.
23. Cerroni L, Rieger E, Hodl S et al. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am. J. Surg. Pathol. 1992 16 543 552.
24. Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J. Cutan. Pathol. 2006 33 (Suppl. 27 42.
25. Abel EA, Lindae ML, Hope RT et al. Benign and malignant forms of erythroderma: cutaneous immunophenotypic characteristics. J. Am. Acad. Dermatol. 1988 19 1089 1095.
26. Ortonne N, Le Gouvello S, Mansour H et al. CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sezary Syndrome. J. Invest. Dermatol. 2008 128 465 472.
27. Diwan AH, Prieto VG, Herling M et al. Primary Sezary Syndrome shows low-grade cytologic atypia and an absence of epidermotropism. Am. J. Clin. Pathol. 2005 123 510 515.
28. Goteri G, Simonetti O, Rupoli S et al. Differences in surviving location and bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study. Br. J. Dermatol. 2007 157 41 48.
29. Kummer JA, Vermeer MH, Dukers D et al. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J. Invest. Dermatol. 1997 109 636 640.
30. Lu D, Patel KA, Duvic M et al. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J. Cutan. Pathol. 2002 29 465 472.
31. Felgar RE, Salhany KE, Macon WR et al. The expression of TIA-1+ cytolytic granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum. Pathol. 1999 30 228 236.
32. Crowson AN, Baschinsky DY, Kovatich A et al. Granulomatous eccrinotropic lymphomatoid papulosis. Am. J. Clin. Pathol. 2003 119 731 739.
33. Flann S, Orchard GE, Wain M et al. Three cases of lymphomatoid papulosis with a CD56+ immunophenotype. J. Am. Acad. Dermatol. 2006 55 903 906.
34. Shabrawi-Caelen LE, Kerl H, Cerroni L. Lymphomatoid papulosis. Arch. Dermatol. 2004 140 441 447.
35. Wu H, Said JW, Ames ED et al. First reported cases of intravascular large cell lymphoma of the NK cell type. Am. J. Clin. Pathol. 2005 123 603 611.
36. Kempf W, Levi E, Kamarashev J et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J. Cutan. Pathol. 2002 29 295 300.
37. Greisser J, Doebbeling U, Roos M et al. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp. Dermatol. 2005 14 380 385.
38. Liang X, Smoller BR, Golitz LE. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders. J. Cutan. Pathol. 2002 29 459 464.
39. McCalmont TH, LeBoit PE. A lymphomatoid papule, but not lymphomatoid papulosis. Am. J. Dermatopathol. 2000 22 188 190.
40. Rose C, Starostik P, Broecker EB. Infection with parapox virus induces CD30-positive cutaneous infiltrates in humans. J. Cutan. Pathol. 1999 26 520 522.
41. Mraz-Gernhard S, Natkunam Y, Hoppe RT et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J. Clin. Oncol. 2001 19 2179 2188.
42. Wu W, Hsiang-Ju T. Lymphomatoid papulosis histopathologically simulating angiocentric and cytotoxic T-cell lymphoma. Am. J. Dermatopathol. 2004 26 133 135.
43. Hubinger G, Muller E, Scheffrahn I et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large lymphoma cell line Karpas 299. Oncogene 2001 20 590 598.
44. Takeshita M, Akamatsu M, Ohshima K et al. CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinctive immunological and clinical characteristics. Histopathology 1995 26 539 546.
45. Tokura Y, Sugita K, Yagi H et al. Primary cutaneous anaplastic large cell lymphoma with fatal leukaemic outcome in association with CLA and CCR4-negative conversion. J. Am. Acad. Dermatol. 2007 57 S92 96.
46. Jones D, Ibrahim S, Patel K et al. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. Clin. Cancer Res. 2004 10 5587 5594.
47. Massone C, Kodama K, Salmhofer W et al. Lupus erythematosus panniculitis (lupus profundus): clinical, histopathological, and molecular analysis of nine cases. J. Cutan. Pathol. 2005 32 396 404.
48. Berti E, Tomasini D, Vermeer M et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphomas. Am. J. Pathol. 1999 155 483 492.
49. Robson A, Assaf C, Bagot M et al. CD8+ mycosis fungoides: an anomalous phenotype, not a separate disease. EORTC Task Force. (Submitted).
50. Wenzel J, Gutgemann I, Distelmaier M et al. The role of cytotoxic skin-homing CD8+ lymphocytes in cutaneous cytotoxic T-cell lymphoma and pityriasis lichenoides. J. Am. Acad. Dermatol. 2005 53 422 427.
51. Tomasini D, Tomasini CF, Ceri A et al. Pityriasis lichenoides: a cytotoxic T-cell-mediated skin disorder. Evidence of human parvovirus B19 DNA in nine cases. J. Cutan. Pathol. 2004 31 531 538.
52. Petrella T, Maubec E, Cornillet-Lefebvre P et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am. J. Surg. Pathol. 2007 31 1887 1892.
53. Suchak R, O'Connor S, Robson A. Indolent CD8-positive lymphoid proliferation of the ear. Presentation to the British Society for Dermatopathology, 7 July 2009.
54. Ryan A, Hayes B, Robson A et al. Primary cutaneous peripheral T-cell lymphoma, unspecified, with an indolent clinical course: a distinct peripheral T-cell lymphoma? Presentation British Association of Dermatologists 89th Annual Meeting, July 2009.
55. Lanier LL, Spits H, Phillips JH. The developmental relationship between NK cells and T-cells. Immunol. Today 1992 13 392 394.
56. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev. 1995 146 57 59.
57. Mukai HY, Hasegawa Y, Kojima H et al. Nodal CD8 positive cytotoxic T-cell lymphoma: a distinct clinicopathological entity. Mod. Pathol. 2002 15 1131 1139.
58. Yawalkar N, Scmid S, Braathen LR et al. Perforin and granzyme B may contribute to skin inflammation in atopic dermatitis and psoriasis. Br. J. Dermatol. 2001 144 1133 1139.
59. Cooke CB, Krenacs M, Stetler-Stevenson M et al. Hepatosplenic gamma/delta T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma/delta T-cell origin. Blood 1996 88 4265 4274.
60. Arnulf B, Copie-Bergman C, Delfau-Larue MH et al. Nonhepatosplenic gamma-delta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localisation. Blood 1998 91 1723 1731.
61. Boulland ML, Kanavaros P, Wechsler J et al. Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas. J. Pathol. 1997 183 432 439.
62. Santucci M, Pimpinelli N, Massi D et al. Cytotoxic/natural killer cell cutaneous lymphomas: report of the EORTC cutaneous lymphoma task force workshop. Cancer 2003 97 610 627.
63. Wain EM, Orchard GE, Mayou S et al. Mycosis fungoides with a CD56+ immunophenotype. J. Am. Acad. Dermatol. 2005 53 158 163.
64. Chang SE, Park IJ, Huh J et al. CD56 expression in a case of primary cutaneous CD30+ anaplastic large cell lymphoma. Br. J. Dermatol. 2000 142 766 770.
65. Rakozy CK, Mohamed AN, Vo TD et al. CD56+/CD4+ lymphomas and leukaemias are morphologically, immunophenotypically, cytogenetically and clinically diverse. Am. J. Clin. Pathol. 2001 116 168 176.
66. Bekkenk MW, Kluin PM, Jansen PM et al. Lymphomatoid papulosis with a natural killer-cell phenotype. Br. J. Dermatol. 2001 145 318 322.
67. Gniadecki R, Rossen K, Ralfkier E et al. CD56+ lymphoma with skin involvement. Arch. Dermatol. 2004 140 427 436.
68. Toro JR, Liewehr DJ, Pabby N et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003 101 3407 3412.
69. Willemze R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC cutaneous lymphoma group study of 83 cases. Blood 2008 111 838 845.
70. Shiozawa E, Shiokawa A, Shibata M et al. Autopsy case of CD4-/CD8- cutaneous T-cell lymphoma presenting disseminated pagetoid reticulosis with aggressive granulomatous invasion to the lungs and pancreas. Pathol. Int. 2005 55 32 39.
71. Berti E, Cerri A, Cavicchini S et al. Primary cutaneous γδ T-cell lymphoma presenting as disseminated pagetoid reticulosis. J. Invest. Dermatol. 1991 96 718 723.
72. Pagnanelli G, Bianchi L, Cantonetti M et al. Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma. Acta Derm. Venereol. 2002 82 314 316.
73. Beltraminelli H, Leinweber B, Kerl H et al. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am. J. Dermatopathol. 2009 31 317 322.
74. EORTC Task Force Meeting, Paris, October 2007.
75. Andres P, Lepagney ML, Bureau B et al. Primary cutaneous lymphomas: a study of 37 cases. Int. J. Dermatol. 1997 36 582 586.
76. Kerl H, Cerroni L. Primary B-cell lymphomas of the skin. Ann. Oncol. 1997 8 29 32.
77. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma: clinicopathologic and immunologic study of 83 cases. Cancer 1991 67 2311 2326.
78. Cerroni L, Volkenandt M, Rieger E et al. Bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J. Invest. Dermatol. 1994 102 231 235.
79. Kim BK, Surti U, Pandya AG, Swerdlow SH. Primary and secondary cutaneous diffuse large B-cell lymphomas. Am. J. Surg. Pathol. 2003 27 360 364.
80. Hembury TA, Lee B, Gascoyne RD et al. Primary cutaneous diffuse large B-cell lymphoma. A clinicopathologic study of 15 cases. Am. J. Clin. Pathol. 2002 117 574 580.
81. Fernandez-Vazquez A, Rodriguez-Peralto JL, Martinez MA et al. Primary cutaneous large B-cell lymphoma: the relation between morphology, clinical presentation, immunohistochemical markers, and survival. Am. J. Surg. Pathol. 2001 25 307 315.
82. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000 403 503 511.
83. Lossos IS, Jones CD, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001 98 945 951.
84. Grange F, Petrella T, Beylot-Barry M et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B cell lymphomas. Blood 2004 103 3662 3668.
85. Sundram U, Kim Y, Mraz-Gernhard S et al. Expression of the bcl-6 and MUM-1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J. Cutan. Pathol. 2005 32 227 234.
86. Hoefnagel JJ, Vermeer MH, Jansen PM et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br. J. Dermatol. 2003 149 1183 1191.
87. Kodama K, Massone C, Chott A et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005 106 2491 2497.
88. Dijkman R, Tensen C, Jordanova S et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J. Clin. Oncol. 2006 24 296 305.
89. Leinweber B, Colli C, Chott A et al. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am. J. Dermatopathol. 2004 26 4 13.
90. Colli C, Leinweber B, Mullegger R et al. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J. Cutan. Pathol. 2004 31 232 240.
91. Cerroni L, Arzberger E, Putz B et al. Primary cutaneous follicle centre cell lymphoma with follicular growth pattern. Blood 2000 95 3922 3928.
92. Chimenti S, Cerroni L, Zenahlik P et al. The role of MT2 and anti-bcl-2 protein antibodies in the differentiation of benign from malignant cutaneous infiltrates of B-lymphocytes with germinal centre formation. J. Cutan. Pathol. 1996 23 319 322.
93. Delia D, Borrello MG, Berti E et al. Clonal immunoglobulin rearrangements and normal T-cell receptor, bcl-2 and c-myc in primary cutaneous B-cell lymphomas. Cancer Res. 1989 49 4901 4905.
94. Geelen FAMJ, Vermeer MH, Meijer CJLM et al. Bcl-2 expression in primary cutaneous large B-cell lymphoma is site-related. J. Clin. Oncol. 1998 16 2080 2085.
95. Child FJ, Russell-Jones R, Woolford AJ et al. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br. J. Dermatol. 2001 144 735 744.
96. Bergman R, Kurtin PJ, Gibson LE et al. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch. Dermatol. 2001 137 432 439.
97. Kim BK, Surti U, Pandya A et al. Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridisation analysis of primary and secondary cutaneous follicular lymphomas. Am. J. Surg. Pathol. 2005 29 69 82.
98. Vergier B, Belaud-Rotureau M, Benassy M et al. Neoplastic cells do not carry bcl2-JH rearrangements detected in a subset of primary cutaneous follicle centre B-cell lymphomas. Am. J. Surg. Pathol. 2004 28 748 755.
99. Lawnicki LC, Weisenburger DD, Aoun P et al. The t(14;18) and bcl-2 expression are present in a subset of primary cutaneous follicular lymphoma. Am. J. Clin. Pathol. 2002 118 765 772.
100. Goodlad JR, Krajewski AS, Blatstone PJ et al. Primary cutaneous follicular lymphoma. A clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am. J. Surg. Pathol. 2002 26 733 741.
101. Gronbaek K, Moller PH, Nedergaard T et al. Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br. J. Dermatol. 2000 142 913 923.
102. Yang B, Tubbs RR, Finn W et al. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. Am. J. Surg. Pathol. 2000 24 694 702.
103. Aguilera NS, Tomaszewski MM, Moad JC et al. Cutaneous follicle centre lymphoma: a clinicopathologic study of 19 cases. Mod. Pathol. 2001 14 828 835.
104. Franco R, Fernandez-Vazquez A, Rodriguez-Peralto JL et al. Cutaneous follicular B-cell lymphoma: description of a series of 18 cases. Am. J. Surg. Pathol. 2001 25 875 883.
105. de Leval L, Harris NL, Longtine J et al. Cutaneous B-cell lymphomas of follicular and marginal zone types. Am. J. Surg. Pathol. 2001 25 732 741.
106. Mirza I, Macpherson N, Paproski S et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J. Clin. Oncol. 2002 20 647 655.
107. Baldassano MF, Bailey EM, Ferry JA et al. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma. Comparison of morphologic and immunophenotypic features. Am. J. Surg. Pathol. 1999 23 88 96.
108. Dunphy CH, Nahass GT. Primary cutaneous T-cell-rich B-cell lymphomas with flow cytometric immunophenotypic findings. Arch. Pathol. Lab. Med. 1999 123 1236 1240.
109. Quintanilla-Martinez L, Preffer F, Rubin D et al. CD20+ T-cell lymphoma: neoplastic transformation of a normal T-cell subset. Am. J. Clin. Pathol. 1994 102 483 489.
110. Hultin LE, Hausner MA, Hutlin PM et al. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T-lymphocytes. Cytometry 1993 14 196 204.
111. Takami A, Saito M, Nakao S et al. CD20-positive T-cell chronic lymphocytic leukaemia. Br. J. Haematol. 1998 102 1327 1329.
112. Blakolmer K, Vesely M, Kummer JA et al. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T-(NK/T-) cell lymphomas. Mod. Pathol. 2000 13 766 772.
113. Yao X, Teruya-Feldstein J, Raffeld M et al. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. Mod. Pathol. 2001 14 105 110.
114. Rawal YB, Nuovo GJ, Frambach GE et al. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J. Cutan. Pathol. 2005 32 616 621.
115. Tokuda Y, Fukushima M, Nakazawa K et al. A case of primary Epstein-Barr virus-associated cutaneous diffuse large B-cell lymphoma unassociated with iatrogenic or endogenous immune dysregulation. J. Cutan. Pathol. 2008 35 666 671.
116. Oyama T, Ichimura K, Suzuki R et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am. J. Surg. Pathol. 2003 27 16 26.
117. Clarke LE, Junkins-Hopkins J, Seykora JT et al. Methotrexate- associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J. Am. Acad. Dermatol. 2007 56 686 690.
118. Paul C, Le Tourneau A, Cayuela JM et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch. Dermatol. 1997 133 867 871.
119. Salloum E, Cooper DL, Howe G et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J. Clin. Oncol. 1996 14 1943 1949.
120. Zhang P, Chiriboga L, Jacobson M et al. Mycosis fungoides-like T- cell cutaneous lymphoid infiltrates in patients with HIV infection. Am. J. Dermatopathol. 1995 17 29 35.
121. Kerschmann RL, Berger TG, Weiss LM et al. Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T-cell lineage. Arch. Dermatol. 1995 131 1281 1288.
122. Verma S, Nuovo GJ, Porcu P et al. Epstein-Barr virus and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation. J. Cutan. Pathol. 2005 32 35 39.
123. Nguyen DD, Loo BW, Tillman G et al. Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report. Ann. Hematol. 2003 82 521 525.
124. Gilaberte M, Gallardo F, Bellosillo B et al. Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi's sarcoma. Br. J. Dermatol. 2005 153 828 832.
125. Coyne JD, Banerjee SS, Bromley M et al. Post-transplant T-cell lymphoproliferative disorder/T-cell lymphoma: a report of three cases of T-anaplastic large-cell lymphoma with cutaneous presentation and a review of the literature. Histopathology 2004 44 387 393.
126. Lucioni M, Ippoliti G, Campana C et al. EBV positive primary cutaneous CD30+ large T-cell lymphoma in a heart transplanted patient: case report. Am. J. Transplant. 2004 4 1915 1920.
127. Petrella T, Dalac S, Maynadie M et al. CD4+ CD56+ cutaneous neoplasms: a distinct haematological entity? Am. J. Surg. Pathol. 1999 23 137 146.
128. Child F, Mitchell TJ, Whittaker SJ et al. Blastic natural killer cell and extranodal natural killer cell-like T-cell lymphoma presenting in the skin: report of six cases from the UK. Br. J. Dermatol. 2003 148 507 515.
129. Herling M, Teitell MA, Shen RR et al. TCL1 expression in plasmacytoid dendritic cells (DC2S) and the related CD4+ CD56+ blastic tumours of skin. Blood 2003 101 5007 5009.
130. Laine J, Kunstle G, Obata T et al. The protooncogene TCL1 is an Akt kinase coactivator. Mol. Cell 2000 6 395 407.
131. Petrella T, Meijer CJLM, Dalac S et al. TCL1 and CLA expression in agranular CD4/CD56 haematodermic neoplasms (blastic NK-cell lymphomas) and leukaemia cutis. Am. J. Clin. Pathol. 2004 122 307 313.
132. Reichard KK, Burks EJ, Foucar MK et al. CD4+ CD56+ lineage-negative malignancies are rare tumours of plasmacytoid dendritic cells. Am. J. Surg. Pathol. 2005 29 1274 1283.
133. Pekarsky Y, Hallas C, Croce CM. The role of TCL1 in human T-cell leukaemia. Oncogene 2001 20 5638 5643.
134. Petrella T, Comeau MR, Maynadie M et al. Agranular CD4+ CD56+ haematodermic neoplasm (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am. J. Surg. Pathol. 2002 26 852 862.
135. Feuillard J, Jacob M, Valensi F et al. Clinical and biologic features of CD4+ CD56+ malignancies. Blood 2002 99 1556 1563.
136. Khoury JD, Medeiros LJ, Manning JT et al. CD56+ TdT+ blastic natural killer cell tumour of the skin: a primitive systemic malignancy related to myelomonocytic leukaemia. Cancer 2002 94 2401 2408.
137. Jaye DL, Geigerman CM, Herling M et al. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ haematodermic neoplasms. Mod. Pathol. 2006 19 1555 1562.
138. Talpur R, Jones DM, Alencar AJ et al. CD25 expression is correlated with histological grade and response to denileukin difitox in cutaneous T-cell lymphoma. J. Invest. Dermatol. 2006 126 575 583.
139. Sun T, Akalin A, Rodacker M et al. CD20 positive T cell lymphoma:is it a real entity? J. Clin. Pathol. 2004 57 442 444.
140. Nakarai T, Robertson MJ, Streuli M et al. Interleukin-2 receptor gamma chain expression on resting and activated lymphoid cells. J. Exp. Med. 1994 180 241 251.
141. Gellrich S, Rutz S, Golembowski S et al. Primary cutaneous follicle centre cell lymphomas and large B-cell lymphomas of the leg descend from germinal centre cells. A single cell polymerase chain reaction analysis. J. Invest. Dermatol. 2001 117 1512 1520.
142. Stokkermans-Dubois J, Jouary T, Vergier B et al. A case of primary cutaneous nasal NK/T-cell lymphoma and review of the literature. Dermatology 2006 213 345 349.
143. Stein H, Foss HD, Durkop H. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000 96 3681 3695.
144. Su LD, Kim YH, LeBoit PE et al. Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morphea. J. Cutan. Pathol. 2002 29 135 141.